Seeking Alpha
Research analyst, IPOs, long/short equity
Profile| Send Message|
( followers)  

The following IPOs are expected to price this week:

Berry Plastics Group (NYSE:BERY), which manufactures plastic goods and containers for consumer applications, plans to raise $500 million by offering 29.4 million shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, Berry Plastics Group would command a market value of $2.0 billion. Berry Plastics Group, which was founded in 1967, booked $4.8 billion in sales over the last 12 months. The Evansville, IN-based company plans to list on the NYSE under the symbol BERY. BofA Merrill Lynch, Citi, Barclays and Deutsche Bank are the joint bookrunners on the deal.

Dave & Buster's Entertainment (PLAY), which operates 60 casual dining restaurants with large arcade areas, plans to raise $100 million by offering 7.7 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Dave & Buster's Entertainment would command a market value of $364 million. Dave & Buster's Entertainment, which was founded in 1982, booked $576 million in sales over the last 12 months. The Dallas, TX-based company plans to list on the NASDAQ under the symbol PLAY. Goldman Sachs, Jefferies & Co. and Piper Jaffray are the joint bookrunners on the deal.

Fleetmatics Group (NYSE:FLTX), which is a leading SaaS provider of fleet management solutions, plans to raise $125 million by offering 7.8 million shares at a price range of $15.00 to $17.00. At the midpoint of the proposed range, Fleetmatics Group would command a market value of $588 million. Fleetmatics Group, which was founded in 2004, booked $108 million in sales over the last 12 months. The Dublin, Ireland-based company plans to list on the NYSE under the symbol FLTX. Barclays and BofA Merrill Lynch are the joint bookrunners on the deal.

GlobeImmune (NASDAQ:GBIM), which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C, plans to raise $60 million by offering 5.0 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, GlobeImmune would command a market value of $207 million. GlobeImmune, which was founded in 1995, booked $9 million in sales over the last 12 months. The Louisville, CO-based company plans to list on the NASDAQ under the symbol GBIM. Wells Fargo Securities and Piper Jaffray are the joint bookrunners on the deal.

Javelin Mortgage Investment (NYSE:JMI), an ARMOUR-managed REIT newly formed to acquire mortgage-related assets, plans to raise $125 million by offering 6.3 million shares at a price of $20.00. At the midpoint of the proposed range, Javelin Mortgage Investment would command a market value of $130 million. Javelin Mortgage Investment was founded in 2012. The Vero Beach, FL-based company plans to list on the NYSE under the symbol JMI. Deutsche Bank, Citi, Barclays and Credit Suisse are the joint bookrunners on the deal.

LifeLock (NYSE:LOCK), an online provider of identity theft protection services, plans to raise $165 million by offering 15.7 million shares at a price range of $9.50 to $11.50. At the midpoint of the proposed range, LifeLock would command a market value of $981 million. LifeLock, which was founded in 2005, booked $228 million in sales over the last 12 months. The Tempe, AZ-based company plans to list on the NYSE under the symbol LOCK. Goldman Sachs, BofA Merrill Lynch and Deutsche Bank are the joint bookrunners on the deal.

Luxfer Holdings (NYSE:LXFR), a global materials firm specializing in aluminum, magnesium and zirconium, plans to raise $104 million by offering 8.0 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Luxfer Holdings would command a market value of $341 million. Luxfer Holdings, which was founded in 1996, booked $534 million in sales over the last 12 months. The Salford, United Kingdom-based company plans to list on the NYSE under the symbol LXFR. Credit Suisse and Jefferies & Co. are the joint bookrunners on the deal.

Regulus Therapeutics (NASDAQ:RGLS), an early stage biotech developing microRNAs treatments for multiple serious diseases, plans to raise $50 million by offering 4.5 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Regulus Therapeutics would command a market value of $239 million. Regulus Therapeutics, which was founded in 2007, booked $14 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NASDAQ under the symbol RGLS. Lazard Capital Markets, Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal.

Last week, there were 3 IPO pricings. Qualys (NASDAQ:QLYS), which provides cloud-based IT security and compliance software solutions, was the week's winner, ending up 18% from its IPO price.

Source: 8 U.S. IPOs Planned For The Week Of October 1